Allos Therapeutics to Present at the Citi Investment Research Global Health Care Conference
May 20 2010 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that members
of the Company’s senior management will present on Thursday, May
27, 2010 at 8:30 a.m. ET at the 2010 Citi Investment Research
Global Health Care Conference taking place at the Hilton New
York.
Attendance at the conference is by invitation only. A live audio
webcast of the presentation can be accessed from and available for
replay through a link on the home page and investor relations
section of the Allos corporate website.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2010
and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in the presentation. All forward-looking statements are
based on information currently available to the Company on the date
thereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of these presentations, except as
required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Oct 2023 to Oct 2024